

## Invitation to Xbrane's presentation at the Redeye Late-Stage Life Science Event

Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") (Nasdaq Stockholm: XBRANE) invites investors and analysts to a presentation of the company at the Redeye Late-Stage Life Science Event on August 31.

The event starts at 10 a.m. and Xbrane presents at 11.50 – 12.10. The company will be represented by CEO Martin Åmark. Registration for the Life Science Day and subsequent lunch is done via the link below.

https://www.lyyti.fi/reg/Redeye\_Theme\_Late\_Stage\_Life\_Science\_8141

The presentation will be available on Xbrane's website the following day.

## Contacts

Martin Åmark, CEO M: +46 76 309 37 77 E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR M: +46 76 325 60 90 E: anette.lindqvist@xbrane.com

## About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting SEK 332 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

## Attachments

Invitation to Xbrane's presentation at the Redeye Late-Stage Life Science Event